BioSpace News Archive

Appointment adds extensive expertise in the development of anti-infectives, including bacteriophage therapy to treat P. aeruginosa infections in cystic fibrosis patients

- Inhibition of HER3 by seribantumab reduces tumor volume by 50-100% in preclinical in vivo models containing an NRG1 fusion - - Presentation of the data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -

Jazz Gains Exclusive Global Rights to FAAH Inhibitor PF-04457845 for the Potential Treatment of PTSD Strategically Expands Jazz’s Mid-Stage Neuroscience Pipeline into a New Disease Area and Further Optimizes SpringWorks’ Strategic Focus on Targeted Oncology Jazz to Make Upfront Payment of $35 Million to SpringWorks with Potential Milestone Payments of Up to $375 Million

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed the first technical milestone under the development and license agreement with Medtronic plc (“Medtronic”) (NYSE: MDT), and is due to receive a U.S. $10 million payment. The development and l

Even as healthcare, as a whole, is transitioning slowly towards value-based care for better patient outcomes and improved quality of life, increase in the prevalence of psoriasis, globally, is spurring investments toward its treatment and management methods.

According to Transparency Market Research’s latest report on the global oral contraceptive pills market for the historical period 2017–2018 and forecast period 2019–2027, high incidence of unintended pregnancies, awareness programs by governments and NGOs, increase in maternal age and late pregnancies are projected to drive the global oral contraceptive pills market during the forecast period

The inhalation therapy had been practiced by ancient civilizations in Egypt, India, Greece, and China.

RhoVac AB announces that it is participating this week in the partnering event BIO Europe 2020 Digital.

Nanobiotix global development plan for first-in-class radioenhancer NBTXR3 across several solid tumor indications proceeds as planned with focus on priority pathways in head and neck cancer and immunotherapy

Gmax Biopharm announces that the first dose of GMA301 was given to the patient in its phase 1B trial to investigate the drug efficacy to treat pulmonary arterial hypertension.